Kawasaki H, Suou T, Watanabe K, Yoshida K, Sasaki H, Kishimoto Y, Sugihara T, Ishitobi S, Kanno S, Tsuruhara I
Jpn J Antibiot. 1984 Sep;37(9):1714-28.
Clinical studies on a new cephalosporin antibiotic, cefotaxime (CTX) were carried out in 79 patients with various types of infections in internal medicine. The efficacy rates were 65.8% in 39 cases of respiratory tract infections, 94.1% in 17 cases of biliary tract infections, 75.0% in 12 cases of urinary tract infections, 80.0% in 11 cases of other infections, and 75.3% in all cases. After CTX therapy, body temperature was improved in 76.7% of all 79 patients, particularly being excellent in all cases of biliary tract infections. Furthermore, symptoms such as cough, dyspnea, chest pain, moist rale and anorexia were improved to a great degree after CTX therapy. Adverse reactions and abnormal laboratory findings consisted of mild liver injury in 1 out of 79 cases. CTX was assessed to be an effective antibiotic for various types of infections in internal medicine.
对一种新型头孢菌素抗生素头孢噻肟（CTX）进行了临床研究，研究对象为79例内科各种类型感染患者。39例呼吸道感染患者的有效率为65.8%，17例胆道感染患者的有效率为94.1%，12例尿路感染患者的有效率为75.0%，11例其他感染患者的有效率为80.0%，所有病例的有效率为75.3%。CTX治疗后，79例患者中有76.7%体温恢复正常，尤其是所有胆道感染病例效果极佳。此外，CTX治疗后咳嗽、呼吸困难、胸痛、湿啰音和厌食等症状有很大程度改善。不良反应和实验室检查异常包括79例中有1例出现轻度肝损伤。CTX被评估为治疗内科各种类型感染的有效抗生素。
